State Street Corp Gt Biopharma, Inc. Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.22 - $0.55 $419 - $1,047	-1,905 Reduced 2.33%	79,976 $24,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $58.2 $18,596 - $1.22 Million	-20,895 Reduced 20.33%	81,881 $72,000
Q3 2022 Nov 15, 2022	BUY	$1.81 - $56.1 $15,747 - $488,070	8,700 Added 9.25%	102,776 $181,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $635,731 - $1.21 Million	-387,641 Reduced 80.47%	94,076 $281,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $108,934 - $138,263	-41,898 Reduced 8.0%	481,717 $1.39 Million
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $166,490 - $386,475	54,587 Added 11.64%	523,615 $1.6 Million
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $630,084 - $1.44 Million	94,324 Added 25.17%	469,028 $3.16 Million
Q2 2021 Aug 16, 2021	BUY	$7.19 - $18.96 $2.69 Million - $7.1 Million	374,704 New	374,704 $5.81 Million

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.